Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8

Authors:

Abstract
The threat of smallpox bioterrorism has prompted reconsideration of the need for smallpox vaccination.1-3 Serious adverse events associated with first-generation vaccines such as the New York City Board of Health (Dryvax; Wyeth, Madison, New Jersey), Lister, and Ikeda strains4-8 have raised obstacles to vaccination campaigns in the United States.7-9 Second-generation vaccines such as ACAM2000 (Acambis, Cambridge, Massachusetts) that use a first-generation seed virus but are grown in tissue culture are also usually accompanied by a high frequency of adverse events.10 Developing a vaccine that is safer than first-generation vaccines yet highly immunogenic is crucial to constructing a prevention plan in the event of bioterrorist attack.